Crucell: A global perspective

Crucell: A global perspective

  • Research & development

    • Vaccines in development:
    • Flavimun® yellow fever vaccine.
    • Influenza cell-based seasonal vaccine.1
    • Tuberculosis recombinant AdVac®–based vaccine.
    • Malaria recombinant AdVac®–based vaccine.
    • Ebola and Marburg recombinant AdVac®–based vaccine.
    • HIV recombinant AdVac®–based vaccine.
    • Human monoclonal antibodies in development:
    • Rabies antibody combination.
    • Influenza antibodies.
    • Hepatitis C antibody combination.
      • 1
      Developed by sanofi pasteur using PER.C6®
    • more

  • Technologies

    • PER.C6® human cell line for development and manufacturing.
    • AdVac® used with PER.C6® to develop recombinant vaccines.
    • MAbstract® to discover novel drug targets and identify human monoclonal antibodies.
    • STAR® to enhance yields of recombinant human antibodies and proteins.
    • Virosome a vehicle enabling the use of virus antigens in the making of vaccines.
    • more

  • Products

    • Paediatric:
    • Quinvaxem® fully liquid vaccine to protect against five important childhood diseases.
    • Hepavax-Gene® recombinant hepatitis B vaccine.
    • Epaxal® Junior low dosage, aluminum-free hepatitis A vaccine.
    • MoRu-Viraten® vaccine for protection against measles and rubella.
    • Travel & endemic:
    • Epaxal® aluminum-free hepatitis A vaccine.
    • Vivotif® oral typhoid vaccine.
    • Dukoral® only internationally licensed oral vaccine against cholera (and ETEC).
    • Respiratory:
    • Inflexal® V virosomal adjuvanted influenza vaccine.
    • more

Back to top